TRIMTECH Therapeutics, a biotechnology company based in Cambridge, England, has raised an additional $14 million in seed funding, bringing its total seed round to $47 million.
The extension was led by Johnson & Johnson Innovation – JJDC, Inc. and BGF, which joined existing backers including Cambridge Innovation Capital, DDF, M Ventures, Pfizer Ventures, Eli Lilly and Company, MP Healthcare Venture Management, Cambridge Enterprise Ventures.
TRIMTECH is developing small molecule therapies designed to target and degrade protein aggregates linked to neurodegenerative diseases. The new funding will be used to advance the company’s proprietary platforms and broader portfolio, including CNS-penetrant degraders based on its TRIMTAC and TRIMGLUE targeted protein degradation technologies.
The financing adds to a growing flow of investor interest in targeted protein degradation and in new approaches to treating neurodegenerative disorders, an area where drug development has remained particularly challenging.
The extension was led by Johnson & Johnson Innovation – JJDC, Inc. and BGF, which joined existing backers including Cambridge Innovation Capital, DDF, M Ventures, Pfizer Ventures, Eli Lilly and Company, MP Healthcare Venture Management, Cambridge Enterprise Ventures.
TRIMTECH is developing small molecule therapies designed to target and degrade protein aggregates linked to neurodegenerative diseases. The new funding will be used to advance the company’s proprietary platforms and broader portfolio, including CNS-penetrant degraders based on its TRIMTAC and TRIMGLUE targeted protein degradation technologies.
The financing adds to a growing flow of investor interest in targeted protein degradation and in new approaches to treating neurodegenerative disorders, an area where drug development has remained particularly challenging.